GlassScriptPhysician profile
Varesh R Patel
NPI 1760461289
$16,878.26
in general payments reported to CMS, 2019-2025
79 companies · $3,097 in 2025
The $3,097 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,968 · 2020: $1,847 · 2021: $2,002 · 2022: $1,980 · 2023: $1,817 · 2024: $4,168 · 2025: $3,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,831 · Debt Forgiveness: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,831.31 |
| Debt Forgiveness | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,754.92 | 2019-2025 | |
| Amgen INC. | $1,634.79 | 2019-2025 | Repatha, Repatha, Evenity |
| Photonicare INC | $1,273.89 | 2023-2024 | Otosight Middle Ear Scope |
| Novo Nordisk INC | $1,176.25 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,020.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $983.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $701.33 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.82 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $430.83 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Eisai INC. | $358.86 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.34 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $327.51 | 2023-2025 | Auvelity, Sunosi |
| Novartis Pharmaceuticals Corporation | $312.06 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $300.28 | 2020-2021 | |
| Braeburn INC. | $292.52 | 2023-2025 | Brixadi |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.